Black Diamond Therapeutics (NASDAQ:BDTX) Raised to “Hold” at Wall Street Zen

by · The Cerbat Gem

Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a report released on Saturday, Wall Street Zen reports.

Other equities research analysts also recently issued research reports about the company. TD Cowen restated a “buy” rating on shares of Black Diamond Therapeutics in a research report on Thursday, August 6th. Raymond James Financial reiterated an “outperform” rating on shares of Black Diamond Therapeutics in a research report on Thursday, August 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Black Diamond Therapeutics in a research report on Friday, October 9th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of Black Diamond Therapeutics in a report on Thursday, August 6th. Seven investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $11.00.

View Our Latest Research Report on Black Diamond Therapeutics

Black Diamond Therapeutics Price Performance

NASDAQ BDTX opened at $1.88 on Friday. The company’s 50 day moving average is $1.98 and its 200-day moving average is $2.14. Black Diamond Therapeutics has a 12-month low of $1.60 and a 12-month high of $4.94. The firm has a market cap of $108.01 million, a P/E ratio of -2.51 and a beta of 3.32.

Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.03. Equities analysts expect that Black Diamond Therapeutics will post -0.57 EPS for the current year.

Hedge Funds Weigh In On Black Diamond Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. Beacon Capital Management LLC boosted its holdings in shares of Black Diamond Therapeutics by 64.0% during the 3rd quarter. Beacon Capital Management LLC now owns 25,615 shares of the company’s stock valued at $48,000 after buying an additional 10,000 shares in the last quarter. Brookstone Capital Management purchased a new stake in shares of Black Diamond Therapeutics in the 1st quarter worth about $30,000. Spark Investment Management LLC purchased a new stake in shares of Black Diamond Therapeutics in the 2nd quarter worth about $29,000. Hsbc Holdings PLC purchased a new stake in shares of Black Diamond Therapeutics in the 2nd quarter worth about $46,000. Finally, EFG International AG bought a new position in shares of Black Diamond Therapeutics in the 2nd quarter worth about $50,000. 95.47% of the stock is owned by institutional investors.

About Black Diamond Therapeutics

(Get Free Report)

Black Diamond Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetically defined cancers. The company uses its proprietary MasterKey platform to identify and develop small-molecule therapies designed to address oncogenic mutations across multiple tumor types, including alterations that may be difficult to target with conventional approaches.

Black Diamond’s pipeline has included brain-penetrant therapies for cancers affecting the central nervous system.

Further Reading